-
FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know
Monday, July 19, 2021 - 1:45pm | 601Read More...A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people. The SPAC Deal: Gelesis announced a SPAC merger with Capstar Special Purpose Acquisition Corp (NYSE: CPSR). The deal values the company at a pro forma market...
